Posted in | News

Degussa Admixtures Inc Introduce Rheopel Plus Admixture Improves Water-Repellent/Efflorescence-Control

Degussa Admixtures, Inc. has once again responded to the needs of the concrete industry with the introduction of Rheopel® Plus Water-Repellent/Efflorescence Control (WR/EC) admixture.

Released at the 2006 MCPX Expo in Anaheim, California, this unique, patented formula is a significant BREAKTHROUGH in WR/EC admixtures for the manufactured concrete products (MCP) and precast/prestressed concrete markets. The novel chemistry of Rheopel Plus admixture makes it different from conventional WR/EC admixtures, enabling superior water repellency and secondary efflorescence control, improved primary efflorescence control, enhanced color vibrancy and visual appeal, and increased strength performance. Rheopel Plus admixture also exhibits excellent wind-driven rain resistance and improves material flow and extrusion characteristics.

Recommended for use in architectural block, single-wythe masonry construction, paving stones, segmental retaining wall units, concrete roof tile, and precast/prestressed concrete, Rheopel Plus admixture offers an improved solution for MCP and precast/prestressed concrete producers experiencing problems with water-repellency and efflorescence control.

Kenneth Kruse, Industry Director at Degussa Admixtures stated, “This unique chemistry reinforces the role of Degussa Admixtures, Inc. as a leader in innovation and technology in the MCP and precast/prestressed concrete markets. We provide our customers with technological expertise and solutions that create value.”

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.